We are live on
!
Find out more
Alyeska Investment Group Portfolio holdings
AUM
$35.4B
1-Year Est. Return
33.54%
This Fund
S&P 500
This Quarter
Est. Return
-0.67%
1 Year Est. Return
+33.54%
3 Year Est. Return
+101.08%
5 Year Est. Return
+102.29%
10 Year Est. Return
+544.32%
AUM
$17.5B
AUM Growth
+$1.25B
(+7.7%)
Cap. Flow
+$1.35B
Cap. Flow
% of AUM
7.69%
Top 10 Holdings %
Top 10 Hldgs %
15.74%
Holding
691
New
246
Increased
140
Reduced
132
Closed
135
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Qualcomm
QCOM
|
+$274M |
| 2 |
Apple
AAPL
|
+$233M |
| 3 |
SCHW
Charles Schwab
SCHW
|
+$200M |
| 4 |
Jabil
JBL
|
+$185M |
| 5 |
Zoom
ZM
|
+$163M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$269M |
| 2 |
Oracle
ORCL
|
+$215M |
| 3 |
Estee Lauder
EL
|
+$172M |
| 4 |
Dell
DELL
|
+$160M |
| 5 |
Microsoft
MSFT
|
+$136M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 24.54% |
| 2 | Consumer Discretionary | 14.14% |
| 3 | Healthcare | 13.6% |
| 4 | Industrials | 12.07% |
| 5 | Financials | 9.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
RGLS
426
DELISTED
Regulus Therapeutics
RGLS
| $1.67M | 0.01% |
937,500
| – | – |
|
427
NewAmsterdam Pharma
NAMS
$3.37B
| $1.65M | 0.01% |
85,641
+50,000
| +140% | +$1M |
|
428
Biohaven
BHVN
$2.23B
| $1.61M | 0.01% |
+46,351
| New | +$1.83M |
|
429
CALL
Advantage Solutions
ADV
$364M
| $1.57M | 0.01% |
+19,547
| New | +$1.82M |
|
430
CALL
Clene
CLNN
$60.4M
| $1.56M | 0.01% |
+10,938
| New | +$81.9K |
|
431
Peloton Interactive
PTON
$2.43B
| $1.56M | 0.01% |
460,500
-239,600
| -34% | -$858K |
|
432
Trane Technologies
TT
$106B
| $1.53M | 0.01% |
4,661
+1,951
| +72% | +$620K |
|
433
STAAR Surgical
STAA
$1.26B
| $1.53M | 0.01% |
32,093
-32,092
| -50% | -$1.41M |
|
|
ALTR
434
DELISTED
Altair Engineering Inc
ALTR
| $1.51M | 0.01% |
15,385
-205,384
| -93% | -$18.1M |
|
435
Ibotta
IBTA
$714M
| $1.5M | 0.01% |
+20,000
| New | +$1.86M |
|
|
RNTX
436
Rein Therapeutics
RNTX
$67.6M
| $1.5M | 0.01% |
+540,000
| New | +$2.22M |
|
|
HELP
437
Cybin Inc
HELP
$633M
| $1.46M | 0.01% |
142,233
| – | – |
|
438
CALL
BiomX
PHGE
$1.73M
| $1.45M | 0.01% |
+22,774
| New | +$1.53M |
|
439
Contango Silver & Gold Inc
CTGO
$654M
| $1.44M | 0.01% |
+79,873
| New | +$1.63M |
|
440
Sprinklr
CXM
$1.63B
| $1.43M | 0.01% |
148,761
-148,760
| -50% | -$1.66M |
|
441
BJs Wholesale Club
BJ
$12.3B
| $1.42M | 0.01% |
16,140
-185,581
| -92% | -$15M |
|
442
MeiraGTx Holdings
MGTX
$1.22B
| $1.39M | 0.01% |
330,182
| – | – |
|
443
Eledon Pharmaceuticals
ELDN
$291M
| $1.32M | 0.01% |
+500,000
| New | +$1.19M |
|
|
ETWO
444
CALL
DELISTED
E2open Parent Holdings
ETWO
| $1.31M | 0.01% |
+292,328
| New | +$1.32M |
|
445
Viridian Therapeutics
VRDN
$2.65B
| $1.3M | 0.01% |
100,000
| – | – |
|
|
RWT
446
Redwood Trust
RWT
$575M
| $1.3M | 0.01% |
+200,000
| New | +$1.24M |
|
447
CALL
Finance of America Companies
FOA
$193M
| $1.27M | 0.01% |
+25,827
| New | +$158K |
|
448
Fulcrum Therapeutics
FULC
$293M
| $1.25M | 0.01% |
202,148
| – | – |
|
|
UBX
449
DELISTED
Unity Biotechnology
UBX
| $1.24M | 0.01% |
920,013
| – | – |
|
450
CALL
Alvotech
ALVO
$1.28B
| $1.22M | 0.01% |
100,000
| – | – |
|
Similar funds
SAM
VIA
Alyeska Investment Group's Q2 2024 Portfolio in Review
As of Q2 2024, Alyeska Investment Group held 691 positions worth $17.5B, up 7.7% from $16.2B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Alyeska Investment Group deployed $1.35B of net new capital in Q2 2024, opening 246 new positions and adding to 140 existing holdings. Its largest new stake was Qualcomm: 1,450,565 shares worth $289M.
By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 22% a quarter earlier, followed by Consumer Discretionary and Healthcare.
On the sell side, the largest reduction was Oracle, an estimated $215M trimmed.
- Alyeska Investment Group's largest Q2 2024 buy was Qualcomm: 1,450,565 shares worth $289M.
- Alyeska Investment Group added most to Zoom in Q2 2024, an estimated $163M increase.
- Alyeska Investment Group's biggest Q2 2024 reduction was Oracle, cutting an estimated $215M.
- Alyeska Investment Group fully exited Alphabet (Google) Class A in Q2 2024, selling an estimated $269M.
- Alyeska Investment Group's ten largest holdings make up 16% of its $17.5B portfolio in Q2 2024.
- Alyeska Investment Group opened 246 new positions and closed 135 in Q2 2024.
- Alyeska Investment Group's portfolio value rose 7.7% quarter-over-quarter to $17.5B.
Based on Alyeska Investment Group's 13F filing for Q2 2024, filed 14 Aug 2024.